Journal of Practical Oncology ›› 2022, Vol. 36 ›› Issue (3): 283-287.doi: 10.11904/j.issn.1002-3070.2022.03.017

• Review • Previous Articles     Next Articles

Progress in the treatment of T1 high-grade urothelial carcinoma

WANG Leilei, CHEN Hui   

  1. Department of Urology,Harbin Medical University Cancer Hospital,Harbin 150081,China
  • Received:2021-09-24 Revised:2021-12-09 Online:2022-06-28 Published:2022-06-28

Abstract: Bladder cancer is a common tumor of the urinary system.More than 90% of bladder cancers are urothelial carcinoma.According to the depth of tumor invasion,it can be divided into non-muscle invasive urothelial carcinoma(NMIBC)and muscular invasive urothelial carcinoma.NMIBC has a good prognosis,which mainly refers to tumor invasion into lamina propria(T1),mucosal layer(Ta)and carcinoma in situ(Tis).Among them,Ta and T1 stage tumors account for the majority.Although both belong to NMIBC,their biological characteristics are different from each other.Because of the abundance of blood vessels and lymphatic vessels in lamina propria,T1 stage tumors are more prone to spread and recurrence.This article will focus on different treatment methods for T1 high-grade urothelial carcinoma,including surgical treatment,interventional therapy,drug chemotherapy,immunotherapy,etc.,and especially discusses how to use surgical treatment and surgical treatment combined with chemotherapy to improve the treatment effect,reduce recurrence and improve the survival time.

Key words: T1 high-grade urothelial carcinoma, Bladder perfusion, Transurethral resection of bladder tumor

CLC Number: